Salvarx Share Discussion Threads

[fig1] 14/3/2018 16:47

He may mention it or it will appear as part of a portfolio of options on a slide presentation. I hold.

[blueball] 13/3/2018 10:34

Kumo Bull break-out yesterday.

[fillipe] 12/3/2018 14:42

edit.

March 9 2018....180p - Northland reiterated their 180p tp, first mentioned 23-10-2017 although there's been some strong news since that 10/2017 mention.

Only 36.47m shares in total here at SALV, so still only a tiny market cap - barely over £10m, even after today's uplift of now abt 29p at the best ask.

Cheap.

f

[the stigologist] 12/3/2018 10:50

Jim Mellon retweeted this

[fillipe] 12/3/2018 10:29

+ 49%....!

f

[the stigologist] 12/3/2018 10:22

does look that way

[wiseacre] 12/3/2018 10:08

This company is hugely undervalued.

[the stigologist] 08/3/2018 12:36

Ian Walters, CEO of SalvaRx, said: "I am delighted with the portfolio of assets that we have put together as well as the teams behind these technologies. We have seen substantial progress across the portfolio and now are beginning to evolve into a clinical stage company with multiple assets expected in the clinic by the end of the year. The appetite for early stage immuno-oncology assets is still strong with recent record-breaking deals showing significant premiums (in February Bristol Myers Squibb acquired 35% of Nektar's compound NKTR-214 for $1.8billion upfront with additional milestones). Analysts also predict that recent tax reform in the US will stimulate additional mergers and acquisitions in this area. SalvaRx is well poised to deliver a series of novel first in class products which can augment the pipelines in big pharma."

[the stigologist] 23/10/2017 08:09

Hmm no wonder Jim Mellon getting himself some 'cheap' warrants then!

[wiseacre] 10/10/2017 15:26

I am told the investment in Iox is worth £100 million Could be one to tuck away. Floated at 33p and looks cheap.

[fig1] 01/10/2017 17:57

Syncona(SYNC) on the up.Very similar business model to SALV.Regards,Fig.

[pugugly] 26/9/2017 16:32

All very interesting but nowhere can I find in th erns the share of the JV vested in SalvaRx. Very important - If I have missed can someone please advise also how much equity put in by the other party - parties - also lerms of licence - Otherwise very much a "pig in a poke" or give a link to the location of this data.

[the stigologist] 26/9/2017 15:49

Looks like some interesting deals being done

[happyholder123] 09/9/2017 11:28

HNR -
TWO wells successfully drilled with abundant oil and gas in samples extracted!
Fracking and FIRST OIL next month!
Don't miss this train!

[wiseacre] 31/7/2017 16:24

I am given to understand Intensity Therapeutics first patient is brown bread.

[fig1] 31/7/2017 10:04

AGM today.Fig.

[spectoacc] 20/7/2017 16:32

String of small sells today - seen no news, nor aware of when we'll get trial news, other than that it'll have to come eventually.

[andymunchkin] 28/6/2017 18:26

i believe the guinea pig(I mean one patient)isthtit????
size ofplacingis

[fig1] 23/6/2017 18:24

Okay,186k buy on 21st is some vote of confidence.Fig.

[doodlebug4] 22/6/2017 13:06

News from last week;

Intensity Therapeutics Issued New Patents for Technology Platform
US Patent 9,636,406 broadens existing claims for the Company’s proprietary technology
Australia intends to grant the Company patent 2013318338
June 15, 2017 07:35 AM Eastern Daylight Time
WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent and Trademark Office (PTO) issued the Company patent 9,636,406. In addition, the Company noted that the Australian PTO intends to grant Intensity patent 2013318338.

“IntensityR17;s DfuseRxSM platform has identified our lead drug, INT230-6. This novel product, now in clinical trials, has shown great promise in regressing tumors and extending life in animal models of metastatic cancer,” said Intensity’s President and CEO, Lewis H. Bender. “The newly issued U.S. patent and soon-to-be issued Australian patent allow us to protect our unique technology. The Company now has multiple issued patents and several patent applications in the U.S. and countries around the world. U.S. patent 9,636,406 and near-term issuance of Australian patent 2013318338 increases the likelihood that our products can be secured in important markets.”